BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Stroke clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for stroke: 197 (149 sponsors; 34 newly posted in the last 180 days, 9 stopped in the last 180 days; 20 new-entrant sponsors). Momentum score 13.2, rank 52 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 10, Phase 2 34, Phase 3 24, Phase 4 8, N/A 121.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Regeneron Pharmaceuticals REGN4P3 3, P2 121
Eli Lilly and Company LLY3P3 2, P2 110
Novartis Pharmaceuticals NVS2P3 200
CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.2NA 1, P3 101
Pharmazz, Inc.2P4 1, P3 101
Biocells (Beijing) Biotech Co.,Ltd1P3 100
Boehringer Ingelheim1P3 100
Corxel Pharmaceuticals1P3 100
Cytopeutics Sdn. Bhd.1P3 101
DiaMedica Therapeutics Inc DMAC1P3 101
Janssen Research & Development, LLC1P3 100
Jiangsu Simcere Pharmaceutical Co., Ltd. new entrant1P3 110
Khondrion BV1P3 100
Merz Pharmaceuticals GmbH1P3 100
Moleac Pte Ltd.1P3 100
Shanghai Hutchison Pharmaceuticals Limited1P3 100
Shin Poong Pharmaceutical Co. Ltd.1P3 101
Supergene, LLC1P3 100
Tasly Biopharmaceuticals Co., Ltd. new entrant1P3 110
Tatchempharmpreparaty, JSC1P3 100
Boston Scientific Corporation BSX4NA 400
Neuralink Corp4NA 410
Abbott Medical Devices3NA 300
iVascular S.L.U.3NA 300
AcQumen Medical, Inc. new entrant2NA 220

New-entrant sponsors: Jiangsu Simcere Pharmaceutical Co., Ltd., Tasly Biopharmaceuticals Co., Ltd., AcQumen Medical, Inc..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P2/P3Cytopeutics Sdn. Bhd.NCT06129175 UCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX)Acute Ischemic Strokerecruiting80
2026-12 est.P2/P3DiaMedica Therapeutics Inc DMACNCT05065216 Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)Acute Stroke; Ischemic Stroke; Strokerecruiting728
2026-12 est.P2NoNO Inc.NCT06403267 NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular ThrombectomyAcute Ischemic Strokerecruiting600
2026-12-10 est.P2Shanghai Pharmaceuticals Holding Co., LtdNCT05686642 Efficacy and Safety of LT3001 on Treating the Acute Ischemic StrokeAcute Ischemic Strokerecruiting300
2026-12-30 est.P2ThromBio Pty. Ltd.NCT06813651 Safety, Tolerability and Efficacy of Adjunctive TBO-309 in Reperfusion for Stroke With Tandem OcclusionIschemic Stroke; Tandem Occlusionrecruiting78
2026-12-31 est.P2Lumosa Therapeutics Co., Ltd.NCT05198323 A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVTAcute Ischemic Strokeactive not recruiting66

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-31 est.P2Changzhou Qianhong Bio-pharma Co., Ltd.NCT07396337 Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.Acute Ischemic Strokerecruiting320
2026-10-29P2Tisento TherapeuticsNCT06961344 An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)terminated37
2026-10-18 est.P2Kunming Pharmaceuticals, Inc.NCT07279493 Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic StrokeAcute Ischemic Strokerecruiting300
2026-10-15 est.P3Janssen Research & Development, LLCNCT05702034 A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKEIschemic Stroke; Ischemic Attack, Transientactive not recruiting12523
2026-09-23P2EIP Pharma IncNCT06987643 A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic StrokeModerate to Severe Acute Ischaemic Stroke; Ischaemic Strokecompleted45
2026-09-17P2Fujian Shengdi Pharmaceutical Co., Ltd.NCT07233070 HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke.Acute Ischemic Strokecompleted210
2026-08 est.P2Shanghai QuietD Biotechnology Co., Ltd.NCT07581210 Efficacy and Safety of QD202 in Participants With Acute Ischemic Stroke Undergoing Thrombolysis Excluding Endovascular ThrombectomyAcute Ischemic Strokerecruiting120
2026-07 est.P3ZZ Biotech, LLCNCT05484154 Efficacy and Safety Evaluation of 3K3A-APC in Ischemic StrokeIschemic Strokewithdrawn
2026-06-29P2Tisento TherapeuticsNCT06402123 A Phase 2b Study of Zagociguat in Patients With MELASMitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)completed43
2026-06-15P2ShionogiNCT05953480 A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic StrokeAcute Ischemic Strokecompleted680
2026-06-12P2Shaanxi Micot Pharmaceutical Technology Co., Ltd.NCT07205328 A Clinical Trial of MT200605 for the Treatment of Acute Ischemic StrokeAcute Ischemic Strokecompleted360

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "stroke"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.